(Reuters)—Johnson & Johnson’s blockbuster psoriasis drug ustekinumab (Stelara) led to a significant reduction in disease activity in patients with systemic lupus compared with a placebo in a midstage clinical trial, according to data released on Nov. 4. Ustekinumab is already approved for psoriasis, psoriatic arthritis and Crohn’s disease and had third-quarter sales of $1.12 billion….
Lupus Survival Is Improving Slowly
NEW YORK (Reuters Health)—Systemic lupus erythematosus (SLE) mortality has declined during the past 46 years in the U.S.—but more slowly than mortality in the general population, according to a nationwide study. “Based on our experience in the clinic and according to previous reports showing improvement in the short-term (five- to 10-year) survival in lupus, I…
Potential Biomarker for APS Identified
New research examines the role of factor Xa in the pathology of antiphospholipid syndrome (APS) and systemic lupus erythematosus-associated APS. Researchers found that FXa stimulation was mediated by protease-activated receptors and enhanced by IgG from FXa reactive antibody positive patients, which may make IgG FXa reactivity a novel biomarker for future research…
AMP RA/Lupus Network Shares Its Progress
Researchers from the AMP RA/Lupus Network came together in June at the annual FOCIS meeting to share their progress as they perform a systematic molecular deconstruction of human diseases…
Lupus Incidence, Prevalence Differ by Race
NEW YORK (Reuters Health)—Racial and ethnic disparities in systemic lupus erythematosus (SLE) incidence and prevalence are considerable, according to two new studies of data from California and Manhattan. “The most important finding of the population-based California and New York registries is the confirmation of the racial and ethnic disparities of SLE, with the highest incidence…
Care Fragmentation May Increase Risk of SLE Damage & Disease Severity
Despite the wide spread adoption of electronic health records, many systems are unable to exchange data, creating the potential for fragmented care. New research examined the effect of care fragmentation on patients with SLE in the Chicago HealthLNK Data Repository, finding that care fragmentation plays an independent role in an increased frequency of infection and disease-related morbidity damage. Researchers also found a relationship between care fragmentation, race and public insurance…
New SLE Criteria Under Development: A Joint Effort of the ACR & EULAR
MADRID—Systemic lupus erythematosus (SLE) experts in North America and Europe are working together to refine the classification system for the disease, with the goal of producing a new set of criteria that is simpler to use and more scientifically rigorous than any classification approach previously published, speakers involved with the process said at the 2017…
Comorbidities & Risk Factors for Developing SLE
MADRID—Researchers have found that systemic lupus erythematosus (SLE) is independently linked with bipolar disorder and say the findings point to a need for greater awareness of psychiatric problems in patients with SLE. In work led by investigators at Tel Aviv University in Israel and presented at the 2017 Annual European Congress on Rheumatology (EULAR), researchers…
Rituximab May Help Pediatric Patients with SLE
Although rituximab is not indicated for adults with SLE, a recent review suggests that it may be safe and effective for treating pediatric SLE. The review found that rituximab improved renal function and reduced proteinuria in pediatric patients. It may also prevent relapse and improve disease activity…
Newly Diagnosed SLE Patients Have a Greater Risk of Cardiovascular Disease
New research has examined the risk of cardiovascular disease (CVD), as well as myocardial infarction and ischemic stroke, for patients with systemic lupus erythematosus (SLE) in a large-scale population-based study. Researchers found that patients with SLE have a greater than two-fold increased risk of developing CVD. This risk is greatest during the first year after diagnosis and remains elevated for at least five years…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 12
- Next Page »